Clinical Trial Update: BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 study of BMS-354825 (dasatinib) in patients with chronic myeloid leukemia in chronic, accelerated, or blast phases and Philadelphia chromosome-positiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia Philadelphia Chromosome-positive
• Chronic Myeloid Leukemia Accelerated Phase
• Chronic Myeloid Leukemia Blast Phase
• Chronic Myeloid Leukemia Chronic Phase

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Leukemia, Myeloid, Chronic-phase, Leukemia, Lymphoblastic, Acute, Philadelphia-positive | Phase 1 | Status: COMPLETED